Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care

Elisabetta Patorno,Ajinkya Pawar,Jessica M. Franklin,Mehdi Najafzadeh,Anouk Déruaz-Luyet,Kimberly G. Brodovicz,Steven Sambevski,Lily G. Bessette,Adrian J. Santiago Ortiz,Martin Kulldorff,Sebastian Schneeweiss

Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care

2019

Elisabetta Patorno
Ajinkya Pawar
Jessica M. Franklin
Mehdi Najafzadeh
Anouk Déruaz-Luyet
Kimberly G. Brodovicz
Steven Sambevski
Lily G. Bessette
Adrian J. Santiago Ortiz
Martin Kulldorff
Sebastian Schneeweiss

Background: The EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium-glucose cotransporter-2 inhibitor,...

Keywords:

Type 2 Diabetes Mellitus
Internal medicine
Heart failure
Diabetes mellitus
Empagliflozin
Cardiology
Comparative effectiveness research
Sodium-Glucose Cotransporter 2 Inhibitor
Medicine
clinical care
Risk assessment
MEDLINE

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

106

Citations